## MEDP: Medpace Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.7% below STRENGTH zone (4.0-10.0%); PEG 3.45 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($531.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Precision Trading with Medpace Holdings Inc. (MEDP) Risk Zones**
- Source: Stock Traders Daily | 20251210T173600 | Somewhat-Bullish | Relevance: 97%
-  This article details a precision trading analysis for Medpace Holdings Inc. (MEDP), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis, identifying key support and resistance levels.

**2. What Makes Medpace Holdings (MEDP) an Investment Choice?**
- Source: Insider Monkey | 20251209T140513 | Bullish | Relevance: 97%
-  Giverny Capital Asset Management highlighted Medpace Holdings (MEDP) as a key investment in its Q3 2025 investor letter, despite initial concerns leading to a share drop. The firm's conviction grew as Medpace consistently communicated business stability and repurchased 9% of its shares at depressed prices, leading to a significant stock recovery. While recognizing MEDP's potential, Giverny also suggests that some AI stocks may offer even greater and quicker returns.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | BMO Capital | $600 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | BMO Capital | init | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.82M) |
| Sells | 29 ($217.29M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 8.4% (-4.4%)
- Vanguard Group Inc: 8.1% (-4.5%)
- AQR Capital Manageme: 3.6% (+65.1%)
- Wasatch Advisors LP: 3.3% (-2.1%)
- State Street Corpora: 2.4% (-4.8%)

### Key Risks

1. Heavy insider selling: $217M sold (29 transactions in 90 days).
2. Valuation stretched: PEG 3.5x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.45 signals overvaluation risk, limited margin of safety. Forward P/E 34.3x stretched relative to 9% growth. Quality metrics strong (ROE 74%, ROA 16%, margin 18%). Insider selling cluster ($217.3M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.9B |
| Beta | 1.43 |
| 52W Range | $250.05 - $626.25 |
| Short Interest | 6.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.45 |
| Forward P/E | 34.3 |
| Current P/E | 37.4 |
| YoY Growth | 9.1% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -9.1% to -4.7% (+4.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 8.7pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.2%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.36x) but short-term weakness (below SMA20). MACD histogram bearish (-5.35), momentum weakening. RSI neutral at 47.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.68% (CS: 13) | Weak |
| RSI_14 | 46.9 | Neutral |
| MACD Histogram | -5.35 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 0.995x | Below |
| vs SMA200 | 1.364x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $566.15
- **Stop Loss:** $531.55 (6.1% risk)
- **Target:** $600.75 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 39
- **Position Value:** $22,079.85
- **Portfolio %:** 22.08%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-09 (Est: $4.21)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.57 | $3.86 | +8.1% |
| 2025Q2 | $3.00 | $3.10 | +3.5% |
| 2025Q1 | $3.07 | $3.67 | +19.6% |
| 2024Q4 | $3.12 | $3.68 | +18.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*